Brief: Cardiff Oncology Announces Positive Data From Investigator-Initiated Trial Of Onvansertib In Combination With Paclitaxel
02/06/2025 22:10
June 2 (Reuters) - Cardiff Oncology Inc CRDF.O: CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM INVESTIGATOR-INITIATED TRIAL OF ONVANSERTIB IN COMBINATION WITH PACLITAXEL IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT ASCO 2025 Source text: ID:nGNX1cH39b Further company coverage: CRDF.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering